TLDR:
- Cell BioEngines, a NYC-based company focused on stem cell research, raised an additional $2M in funding.
- The funding round was led by SOSV, the Partnership Fund, and Empire State Development’s NY Ventures.
Cell BioEngines, led by CEO Dr. Ajay Vishwakarma, is a biotech company developing stem cell-derived therapies for human disease treatment. The company plans to use the funds to expand operations and research and development. The funding will support the company’s first multicenter clinical trial aimed at hematological cancer patients who are unable to find a donor for HLA-haploidentical blood stem cell transplants. This trial represents a new approach using expanded cord blood-derived hematopoietic cell therapy. Cell BioEngines’ vision is to deliver ‘off-the-shelf’ cell-based therapies to patients.
